source
- Axoltis reports Phase 2 failure of experimental ALS drug but notes small signalAxoltis Pharma, a French biotech, announced that its Phase 2 trial of an experimental ALS therapy did not meet its primary endpoints. The company said the data were noisy but observed a modest tre…
- FDA opens pilot to accelerate phase 1 trials with fast IND reviewsThe Food and Drug Administration announced a new pilot program aimed at speeding up early-stage clinical trials in the United States. The initiative pairs drug sponsors with qualified research inst…